StreetAlpha.app
Home › Stocks › RGNX

REGENXBIO Inc. (RGNX)

Healthcare
$7.16
▼ −0.28%
LAST CLOSE · NOV 20

REGENXBIO develops gene therapies that use AAV vectors to deliver working genes into cells to treat disease. It last closed at $7.16 on Nov 20, down 0.28% on the day. The next earnings report for RGNX is expected around Thu, Mar 4, 2027. For the quarter ended Sep 2026, RGNX reported EPS of -$0.62 on revenue of $9.2M, with revenue down 69.2% from a year ago. Over its last 8 reports the stock moved an average of 8.4% the session after earnings. Over the last 12 months RGNX insiders bought $949K of stock on the open market and sold $940K, according to SEC Form 4 filings.

AI Auto Pilots
Is RGNX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RGNX.

Key Stats

Last 12 months
Results
Revenue
$153.9M
−4.6% vs a year ago
Net income
−$175.2M
−113.9% margin
EPS (diluted)
−$3.20
Free cash flow
−$154.8M
−100.6% margin
Valuation
Market cap
$473.4M
66.1M shares
P/E
–
No P/E while losing money
Price to sales
3.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$95.8M
At Sep 30
Shareholder equity
$148.0M
Shares outstanding
66.1M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $470.3M$470.3MFY2021FY2022: $112.7M$112.7MFY2022FY2023: $90.2M$90.2MFY2023FY2024: $83.3M$83.3MFY2024FY2025: $170.4M$170.4MFY2025

From RGNX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 4
Estimated date · Time not announced
Reported EPS
-$0.62
Quarter ended Sep 2026
Year ago EPS
-$1.20
Same quarter last year
Revenue
$9.2M
−69.2% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.00Dec '24Mar 2025: $0.12Mar '25Jun 2025: -$1.38Jun '25Sep 2025: -$1.20Sep '25Dec 2025: -$1.30Dec '25Mar 2026: -$1.72Mar '26Jun 2026: $0.43Jun '26Sep 2026: -$0.62Sep '26Latest -$0.62
Revenue by quarter
Dec 2024: $21.2MDec '24Mar 2025: $89.0MMar '25Jun 2025: $21.4MJun '25Sep 2025: $29.7MSep '25Dec 2025: $30.3MDec '25Mar 2026: $6.4MMar '26Jun 2026: $108.0MJun '26Sep 2026: $9.2MSep '26Latest $9.2M
How RGNX moved after its last 8 reports
Average move the session after a report ±8.4%
Nov 5, 2026Time not announced−4.3%
Aug 6, 2026Time not announced+7.4%
May 14, 2026Time not announced−37.8%
Mar 5, 2026Time not announced−4.6%
Nov 6, 2025Time not announced−3.8%
Aug 7, 2025Time not announced−4.0%
May 12, 2025After the close+2.6%
Mar 13, 2025After the close+2.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RGNXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RGNX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RGNX

Technical Analysis

RGNX · as of the Nov 20 close · updated each morning
Downtrend

The stock is 4% below its 20 day and 5% below its 50 day average. It is 23% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 45). The nearest support is the swing low (Sep 24) at $7.12, and the nearest resistance the swing high (Jun 1) at $7.32.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 7.7%/day
Key levels
$16.1952 week high+126.1%
$9.10100 day average+27.1%
$8.79200 day average+22.8%
$7.5150 day average+4.9%
$7.4320 day average+3.8%
$7.35Pivot R1+2.7%
$7.32Swing high (Jun 1)+2.2%
$7.16Last close
$7.12Swing low (Sep 24)−0.6%
$7.11Pivot−0.7%
$6.91Pivot S1−3.5%
$5.4652 week low−23.7%
Indicators
RSI (14)44.86Middle of its rangeNeutral
MACD-0.06Below its signal lineBearish
Stochastic17.9Near the bottom of its rangeOversold
ADX (14)12.1No clear trend
Williams %R-84.1Oversold below −80, overbought above −20Oversold
CCI (20)-64.5Oversold below −100, overbought above 100Neutral
Rate of change−6.0%Change over 10 sessionsBearish
ATR (14)$0.55Typical daily range, 7.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RGNX

What happened before

See how RGNX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RGNX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RGNX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RGNXHow many large options trades hit RGNX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

RGNX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲110 buying vs 64 selling
  • ▲Held by funds +18.0 pts
  • ▲Funds holding +8
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding174166+4.8%
In funds' top 1012−50.0%
Held by funds82.1%64.1%+18.0 pts
New / increased33 / 7725 / 62+26.4%
Reduced / sold out41 / 2352 / 35−26.4%
Put/call ratio1.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RGNX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RGNX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$949K1 buy · 1 insider
Sold$940K4 sales · 1 insider
27% of the selling was under pre-arranged trading plans.
2026-03 sold $53K2026-05 sold $169K2026-07 sold $718K2026-08 bought $949KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 27Gregory Austin CiongoliDirectorBuy102,603$9.25$949K
Jul 2Steve PakolaChief Medical OfficerSale plan2,161$13.64$29K
Jul 1Steve PakolaChief Medical OfficerSale56,333$12.23$689K
May 11Steve PakolaChief Medical OfficerSale plan15,309$11.02$169K
Mar 10Steve PakolaChief Medical OfficerSale plan5,124$10.35$53K
Oct 9, 2025Curran SimpsonCEOSale plan20,811$12.62$263K
Every insider buy and sale for RGNX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RGNX insider trades →

From SEC Form 4 filings by RGNX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RGNX is in one of them and how their past RGNX trades turned out.

RGNX in the AI portfolios
Loading…

RGNX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RGNX in an article yet. Here's the latest on the wider market.

RGNX in the news

RGNX Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Nov 14
Who traded RGNX · since 2019
Latest 2 filings
$1K – $15KTraded Nov 8, 2019Filed Nov 14, 2019
$1K – $15KTraded Oct 22, 2019Filed Nov 14, 2019
PersonTypeAmountTradedFiledDelay
Peter WelchD · VTSell$1K – $15KNov 8, 2019Nov 14, 20196 d
Peter WelchD · VTBuy$1K – $15KOct 22, 2019Nov 14, 201923 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About REGENXBIO

REGENXBIO is a biotechnology company based in Rockville, Maryland, that develops gene therapies. Its treatments use modified viruses called AAV vectors, which are designed to deliver working genes into cells. The company's own pipeline targets eye, muscle and nervous system diseases. It also licenses its vector platform to drugmakers such as AbbVie and Novartis, which develop treatments for their own patients.

Headquarters
Rockville, MD